Evidence map›Paper›PMID 16434977›Full record

ArticleOncogene2006

Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.

J Gong, J Zhu, O B Goodman, R G Pestell, P N Schlegel, D M Nanus, R Shen

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 74 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Regulators of gene expression as biomarkers for prostate cancer.American journal of cancer research · 2012
    Article
  16. SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2011
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

J GongDepartment of Urology, Weill Medical College of Cornell University, New York, NY 10021, USA.
J Zhu
O B Goodman
R G Pestell
P N Schlegel
D M Nanus
R Shen
Presbyterian Hospital · USNewYork–Presbyterian Hospital · USGeorgetown University Medical Center · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5M
CYCLIN D1 FUNCTION IN PROSTATE CANCERR01CA086072 · NCI · YESHIVA UNIVERSITY · PI PESTELL, RICHARD G · 2001 to 2013
$3.3M
NEUTRAL ENDOPEPTIDASE INACTIVATION IN ADVANCED PROSTATER01CA080240 · NCI · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI NANUS, DAVID M. · 1998 to 2005
$1.9M
Cyclin D1 Regulation of Nuclear Receptor Function in Breast CancerR01CA107382 · NCI · THOMAS JEFFERSON UNIVERSITY · PI PESTELL, RICHARD G · 2004 to 2008
$1.6M
Caveolin-1 and Cyclin D1 in Mammary TumorigenesisR01CA093596 · NCI · YESHIVA UNIVERSITY · PI PESTELL, RICHARD G · 2002 to 2006
$1.4M
Neuropeptide Signaling in Prostate CancerR01DK060908 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI SHEN, RUOQIAN · 2003 to 2006
$1.2M
NCI NIH HHS P30CA51008-14NCI NIH HHS R01CA107382NCI NIH HHS R01 CA80240NCI NIH HHS R01CA86072NCI NIH HHS R01CA93596-01NIDDK NIH HHS R01 DK060908-02
6 · The paper itself

Abstract

Androgen receptor signaling in prostate cancer cells is augmented by the androgen receptor (AR) coactivator p300, which transactivates and acetylates the AR in the presence of dihydrotestosterone (DHT). As prostate cancer (PC) cells progress to androgen independence, AR signaling remains intact, indicating that other factors stimulate AR activities in the absence of androgen. We previously reported that neuropeptide growth factors could transactivate the AR in the presence of very low concentrations of DHT. Here, we examine the involvement of p300 in neuropeptide activation of AR signaling. Transfection of increasing concentrations of p300 in the presence of bombesin into PC-3 cells resulted in a linear increase in AR transactivation, suggesting that p300 acts as a coactivator in neuropeptide-mediated AR transactivation. P300 is endowed with histone acetyltransferase (HAT) activity. Therefore, we examine the effect of bombesin on p300 HAT activity. At 4 h after the addition of bombesin, p300 HAT activity increased 2.0-fold (P<0.01). Incubation with neutral endopeptidase, which degrades bombesin, or bombesin receptor antagonists blocked bombesin-induced p300 HAT activity. To explore the potential signaling pathways involved in bombesin-induced p300 HAT activity, we examined Src and PKCdelta pathways that mediate bombesin signaling. Inhibitors of Src kinase activity or Src kinase siRNA blocked bombesin-induced p300 HAT activity, whereas PKCdelta inhibitors or PKCdelta siRNA significantly increased bombesin-induced p300 HAT activity suggesting that Src kinase and PKCdelta kinase are involved in the regulation of p300 HAT activity. As AR is acetylated in the presence of 100 nM DHT, we next examined whether bombesin-induced p300 HAT activity would result in enhanced AR acetylation. Bombesin-induced AR acetylation at the same motif KLKK observed in DHT-induced acetylation. Elimination of p300 using p300 siRNA reduced AR acetylation, demonstrating that AR acetylation was mediated by p300. AR acetylation results in AR transactivation and the expression of the AR-regulated gene prostate-specific antigen (PSA). Therefore, we examined bombesin-induced AR transactivation and PSA expression in the presence and absence of p300 siRNA and found inhibition of p300 expression reduced bombesin-induced AR transactivation and PSA expression. Together these results demonstrate that bombesin, via Src and PKCdelta signaling pathways, activates p300 HAT activity which leads to enhanced acetylation of AR resulting in increased expression of AR-regulated genes.

Indexed as

AcetylationBlotting, WesternBombesinCell Cycle ProteinsCell Line, TumorEnzyme ActivationHistone AcetyltransferasesHumansMalep300-CBP-Associated Factorp300-CBP Transcription FactorsProstate-Specific AntigenProstatic NeoplasmsProtein Kinase C-deltaReceptors, AndrogenRNA, Small InterferingBombesinCell Cycle ProteinsHistone Acetyltransferasesp300-CBP-Associated Factorp300-CBP Transcription FactorsProstate-Specific AntigenProtein Kinase C-deltaReceptors, AndrogenRNA, Small InterferingTranscription Factors

Identifiers

PMID16434977
OpenAlexW2071705420

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.